NYSE:NVO - Novo Nordisk A/S Stock Price, Forecast & News

Novo Nordisk A/S trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO."

Novo Nordisk A/S announced a semi-annual dividend on Friday, February 7th. Shareholders of record on Monday, March 30th will be paid a dividend of $0.7874 per share on Tuesday, April 7th. This represents a yield of 1.4%. The ex-dividend date is Friday, March 27th. This is an increase from Novo Nordisk A/S's previous semi-annual dividend of $0.32. View Novo Nordisk A/S's Dividend History.

Novo Nordisk A/S (NYSE:NVO) announced its quarterly earnings results on Friday, November, 1st. The company reported $0.64 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.62 by $0.02. The business had revenue of $4.51 billion for the quarter, compared to analyst estimates of $4.55 billion. Novo Nordisk A/S had a return on equity of 73.70% and a net margin of 31.95%. View Novo Nordisk A/S's Earnings History.

Novo Nordisk A/S is scheduled to release their next quarterly earnings announcement on Friday, May 1st 2020. View Earnings Estimates for Novo Nordisk A/S.

Novo Nordisk A/S updated its FY 2020 IntraDay earnings guidance on Wednesday, February, 5th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $18.852-19.401 billion, compared to the consensus revenue estimate of $18.74 billion.

9 brokerages have issued 1-year price objectives for Novo Nordisk A/S's stock. Their forecasts range from $51.85 to $400.00. On average, they expect Novo Nordisk A/S's share price to reach $214.82 in the next twelve months. This suggests a possible upside of 236.4% from the stock's current price. View Analyst Price Targets for Novo Nordisk A/S.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last year. There are currently 1 sell rating, 5 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novo Nordisk A/S.

Media stories about NVO stock have trended somewhat negative on Sunday, InfoTrie reports. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Novo Nordisk A/S earned a news impact score of -1.8 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Novo Nordisk A/S.

Some companies that are related to Novo Nordisk A/S include Johnson & Johnson (JNJ), Roche Holdings AG Basel (RHHBY), Novartis (NVS), Merck & Co., Inc. (MRK), Pfizer (PFE), Abbott Laboratories (ABT), AbbVie (ABBV), Eli Lilly And Co (LLY), AstraZeneca (AZN), Sanofi (SNY), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Commonwealth Bank of Australia (CSLLY), Celgene (CELG) and Bayer (BAYRY).

Based on aggregate information from My MarketBeat watchlists, some companies that other Novo Nordisk A/S investors own include Gilead Sciences (GILD), AbbVie (ABBV), Pfizer (PFE), Johnson & Johnson (JNJ), NVIDIA (NVDA), AT&T (T), QUALCOMM (QCOM), Starbucks (SBUX), Alibaba Group (BABA) and Cisco Systems (CSCO).

Novo Nordisk A/S's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (1.11%), Loomis Sayles & Co. L P (0.92%), Bank of America Corp DE (0.48%), State Street Corp (0.19%), Everett Harris & Co. CA (0.13%) and Sustainable Growth Advisers LP (0.11%). View Institutional Ownership Trends for Novo Nordisk A/S.

NVO stock was sold by a variety of institutional investors in the last quarter, including Sustainable Growth Advisers LP, Bank of America Corp DE, State Street Corp, NorthCoast Asset Management LLC, Credit Suisse AG, Alyeska Investment Group L.P., Hikari Power Ltd and Boston Partners. View Insider Buying and Selling for Novo Nordisk A/S.

NVO stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, First Trust Advisors LP, Loomis Sayles & Co. L P, Capital International Investors, Amundi Pioneer Asset Management Inc., Bain Capital Public Equity Management II LLC, Connor Clark & Lunn Investment Management Ltd. and Beacon Investment Advisory Services Inc.. View Insider Buying and Selling for Novo Nordisk A/S.

Shares of NVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NVO stock can currently be purchased for approximately $63.85.

Novo Nordisk A/S has a market capitalization of $151.20 billion and generates $18.30 billion in revenue each year. The company earns $5.84 billion in net income (profit) each year or $2.46 on an earnings per share basis. Novo Nordisk A/S employs 43,258 workers across the globe.View Additional Information About Novo Nordisk A/S.

The official website for Novo Nordisk A/S is http://www.novonordisk.com/.

Novo Nordisk A/S's mailing address is Novo Alle, Bagsvaerd G7, 2880. The company can be reached via phone at 45-4444-8888 or via email at [email protected]